The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy
Open accessAbstract
Objectives Obesity and diabetes are strong risk factors that drive the development of type I endometrial cancers. Recent epidemiological evidence suggests that metformin may lower cancer risk and reduce rates of cancer deaths among diabetic patients. In order to better understand metformin's anti-tumorigenic potential, our goal was to assess the effect of metformin on proliferation and expression of key targets of metformin cell signaling in endometrial cancer cell lines. Methods The endometrial cancer cell lines, ECC-1 and Ishikawa, were used. Cell proliferation was assessed after exposure to metformin. Cell cycle progression was evaluated by flow cytometry. Apoptosis was assessed by ELISA for caspase-3 activity. hTERT expression was determined by real-time RT-PCR. Western immunoblotting was performed to determine the expression of the downstream targets of metformin. Results Metformin potently inhibited growth in a dose-dependent manner in both cell lines (IC50 of 1 mM). Treatment with metformin resulted in G1 arrest, induction of apoptosis and decreased hTERT expression. Western immunoblot analysis demonstrated that metformin induced phosphorylation of AMPK, its immediate downstream mediator, within 24 hours of exposure. In parallel, treatment with metformin decreased phosphorylation of S6 protein, a key target of the mTOR pathway. Conclusions We find that metformin is a potent inhibitor of cell proliferation in endometrial cancer cell lines. This effect is partially mediated through AMPK activation and subsequent inhibition of the mTOR pathway. This work should provide the scientific foundation for future investigation of metformin as a strategy for endometrial cancer prevention and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 2×
“Unfortunately, obesity is not only a risk factor for developing endometrial cancer, but it is associated with an increased risk of death [4-6].”
BackgroundMetformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 2×
“This concept is even more intriguing given that metformin has been shown to improve outcomes in diabetic cancer patients as compared to sulfonylureas or insulin use [7,8].”
BackgroundThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318 · cited 1×
“8 ug/mL), and other investigators have calculated 20 uM as a clinically equivalent dose in vitro [38,39].”
BackgroundMetformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k
Jefferies, H. B. J., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., & Thomas, G. (1997) · The EMBO Journal · doi:10.1093/emboj/16.12.3693 · Cited by 934
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 923
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861 · cited 1×
“In contrast, metformin failed to induce apoptosis in prostate and breast cancer cell lines at similar doses of treatment but did block cell cycle progression in G1 phase [30,31].”
BackgroundAltered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers
Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829
Clinical Pharmacokinetics of Metformin
Scheen, A. J. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630050-00003 · Cited by 636
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Alimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7933 · Cited by 523
Metformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall Cells
Isoda, K., Young, J. L., Zirlik, A., MacFarlane, L. A., Tsuboi, N., Gerdes, N., Schönbeck, U., & Libby, P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000201938.78044.75 · Cited by 499
Accumulation of Metformin by Tissues of the Normal and Diabetic Mouse
Wilcock, C., & Bailey, C. J. (1994) · Xenobiotica · doi:10.3109/00498259409043220 · Cited by 418 · cited 1×
“Metformin has also been shown to accumulate in tissues at higher concentrations than in blood, suggesting that increased concentrations of metformin may be achieved in target organs at lower, more pharmacologic doses [40].”
BackgroundEndometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship
Fader, A. N., Arriba, L. N., Frasure, H. E., & von Gruenigen, V. E. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.03.039 · Cited by 354
Zakikhani, M., Dowling, R. J. O., Sonenberg, N., & Pollak, M. N. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0081 · Cited by 294
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald, V., deGraffenried, L. A., Russel, D., Friedrichs, W. E., Ray, R. B., & Hidalgo, M. M. (2002) · PubMed · Cited by 279
In vitro metformin anti-neoplastic activity in epithelial ovarian cancer
Gotlieb, W. H., Saumet, J., Beauchamp, M.-C., Gu, J., Lau, S., Pollak, M. N., & Bruchim, I. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.008 · Cited by 267
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi, Y., Gera, J., Hu, L., Hsu, J.-H., Bookstein, R., Li, W., & Lichtenstein, A. K. (2002) · PubMed · Cited by 231
Cell cycle-dependent modulation of telomerase activity in tumor cells.
Zhu, X., Kumar, R., Mandal, M., Sharma, N., Sharma, H. W., Dhingra, U., Sokoloski, J. A., Hsiao, R., & Narayanan, R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.6091 · Cited by 226
Bièche, I., Noguès, C., Paradis, V., Olivi, M., Bédossa, P., Lidereau, R., & Vidaud, M. (2000) · PubMed · Cited by 204
Targeting AMPK: A new therapeutic opportunity in breast cancer
Hadad, S. M., Fleming, S., & Thompson, A. M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.01.007 · Cited by 173
Telomerase and human tumorigenesis
Stewart, S. A., & Weinberg, R. A. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0339 · Cited by 169
Lack of cell cycle regulation of telomerase activity in human cells
Holt, S. E., Aisner, D. L., Shay, J. W., & Wright, W. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10687 · Cited by 166
Terakawa, N., Kanamori, Y., & Yoshida, S. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100203 · Cited by 161
Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis
Chia, V. M., Newcomb, P. A., Trentham‐Dietz, A., & Hampton, J. M. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.00790.x · Cited by 137
Loss of Lkb1 Provokes Highly Invasive Endometrial Adenocarcinomas
Contreras, C. M., Gurumurthy, S., Haynie, J. M., Shirley, L. J., Akbay, E. A., Wingo, S. N., Schorge, J. O., Broaddus, R. R., Wong, K., Bardeesy, N. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5014 · Cited by 116
Zhou, C., Gehrig, P. A., Whang, Y. E., & Boggess, J. F. (2003) · PubMed · Cited by 91
Self-citationThe impact of obesity and age on quality of life in gynecologic surgery
von Gruenigen, V. E., Gil, K. M., Frasure, H. E., Jenison, E. L., & Hopkins, M. P. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.03.038 · Cited by 90
Lu, K. H., Wu, W., Dave, B., Slomovitz, B. M., Burke, T. W., Munsell, M. F., Broaddus, R. R., & Walker, C. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0321 · Cited by 76
Telomerase Activity in Gynecologic Tumors
Zheng, P., Iwasaka, T., Yamasaki, F., Ouchida, M., Yokoyama, M., Nakao, Y., Fukuda, K., Matsuyama, T., & Sugimori, H. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1996.4523 · Cited by 55
Telomerase Activity in the Female Reproductive Tract and Neoplasms
Yokoyama, Y., Takahashi, Y., Shinohara, A., Lian, Z., & Tamaya, T. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1997.4921 · Cited by 43
Pharmacologic Therapy of Polycystic Ovary Syndrome
Dronavalli, S., & Ehrmann, D. A. (2007) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31802f35a0 · Cited by 41
Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest
Bae-Jump, V. L., Zhou, C., Gehrig, P. A., Whang, Y. E., & Boggess, J. F. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.08.053 · Cited by 35
Self-citationLKB1: a sweet side to Peutz–Jeghers syndrome?
Carling, D. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.02.003 · Cited by 25
Steiner, E., Plata, K., Interthal, C., Schmidt, M., Faldum, A., Hengstler, J. G., Sakuragi, N., Watari, H., Yamamoto, R., & Kölbl, H. (2007) · PubMed · Cited by 25
Cited by
Understanding the benefit of metformin use in cancer treatment
Dowling, R. J., Goodwin, P. J., & Stambolic, V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-33 · Cited by 409
Metformin in cancer: translational challenges
Dowling, R. J. O., Niraula, S., Stambolic, V., & Goodwin, P. J. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0007 · Cited by 355
Repurposing metformin for cancer treatment: current clinical studies
Chae, Y. K., Arya, A., Malecek, M.-K., Shin, D. S., Carneiro, B., Chandra, S., Kaplan, J., Kalyan, A., Altman, J. K., Platanias, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8194 · Cited by 316
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection
Cohen, D. H., & LeRoith, D. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-11-0374 · Cited by 301
Queiroz, E. A. I. F., Puukila, S., Eichler, R., Sampaio, S. C., Forsyth, H. L., Lees, S. J., Barbosa, A. M., Dekker, R. F. H., Fortes, Z. B., & Khaper, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098207 · Cited by 278
Metadata
- Authors
- Cantrell, L. A., Zhou, C., Mendivil, A., Malloy, K. M., Gehrig, P. A., & Bae-Jump, V. L.
- Venue
- Gynecologic Oncology
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 116
- Issue
- 1
- Pages
- 92-98
- ISSN
- 0090-8258 (ISSN-L)
- OpenAlex
- W1969542174
- Cited by
- 331
- References
- 41
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.